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Epigenetic regulation of hematopoietic stem cells
(HSCs) ensures lifelong production of blood and
bone marrow. Recently, we reported that loss of de
novo DNA methyltransferase Dnmt3a results in HSC
expansion and impaired differentiation. Here, we
report conditional inactivation of Dnmt3b in HSCs
either alone or combined with Dnmt3a deletion.
Combined loss of Dnmt3a and Dnmt3b was syner-
gistic, resulting in enhanced HSC self-renewal
and a more severe block in differentiation than in
Dnmt3a-null cells, whereas loss of Dnmt3b resulted
in a mild phenotype. Although the predominant
Dnmt3b isoform in adult HSCs is catalytically inac-
tive, its residual activity in Dnmt3a-null HSCs can
drive some differentiation and generates paradoxical
hypermethylation of CpG islands. Dnmt3a/Dnmt3b-
null HSCs displayed activated b-catenin signaling,
partly accounting for the differentiation block. These
data demonstrate distinct roles for Dnmt3b in HSC
differentiation and provide insights into comple-
mentary de novo methylation patterns governing
regulation of HSC fate decisions.
INTRODUCTION
DNA methylation of CpG dinucleotides is a major mode of
epigenetic regulation in the vertebrate genome with functions
including silencing of repetitive elements, X chromosome inacti-
vation, genomic imprinting, and regulation of gene expression
(Jaenisch and Ja¨hner, 1984; Ng and Bird, 1999; Surani, 1998).
Of the three catalytic DNA methyltransferase enzymes, Dnmt1,
has a higher affinity for hemimethylated DNA than unmethylated
DNA (Bestor, 1992), and ablation of Dnmt1 in embryonic stem350 Cell Stem Cell 15, 350–364, September 4, 2014 ª2014 Elsevier Icells (ESCs) leads to extensive but nonspecific loss of DNA
methylation, leading to the view that Dnmt1 is a ‘‘maintenance’’
methyltransferase (Lei et al., 1996; Li et al., 1992). Conversely,
Dnmt3a and Dnmt3b act as de novo DNA methyltransferases
responsible for the establishment of DNA methylation patterns,
predominantly during early development (Hata et al., 2002;
Okano et al., 1999). However, Dnmt3a and Dnmt3b also appear
important for the stable inheritance of some DNA methylation,
given that a loss of both enzymes in ESCs results in progressive
loss of DNA methylation in repetitive and some single-copy
elements (Chen et al., 2003).
Although Dnmt3a and Dnmt3b are highly homologous, their
biological functions remain unclear. Dnmt3b-null mice die at
midgestation with multiple developmental defects, and
Dnmt3a-null mice die shortly after birth (Okano et al., 1999),
but their cell-type-specific roles have not been fully eluci-
dated. Compound Dnmt3a/Dnmt3b double knockout (DKO)
embryos arrest shortly after gastrulation (Okano et al., 1999),
and DKO ESCs display inefficient differentiation which is
increasingly pronounced with extended passage (Chen
et al., 2003). In neural stem cells, Dnmt3a is required for neu-
rogenesis, given that Dnmt3a-dependent nonproximal pro-
moter methylation regulates expression of neurogenic genes
(Wu et al., 2010).
Our group has recently reported that Dnmt3a is essential for
hematopoietic stem cell (HSC) differentiation, given that
Dnmt3a-null HSCs show a marked decline in differentiation
capacity on a per-HSC basis over serial transplantation, re-
sulting in accumulation of undifferentiated HSCs in the bone
marrow (Challen et al., 2012). Moreover, mutations in
DNMT3A are prevalent in myeloid malignancies (Ley et al.,
2010; Walter et al., 2011; Yan et al., 2011) and lymphoid leu-
kemias (Grossmann et al., 2013), consistent with an important
function in hematopoiesis. However, no distinct role for
Dnmt3b has been identified in HSCs or any other adult stem
cell. Here, we conditionally ablate Dnmt3b alone or in combi-
nation with Dnmt3a and investigate the functional conse-
quences for HSCs.nc.
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Dnmt3s Cooperatively Enable Long-Term HSC
Differentiation In Vivo
Similar toDnmt3a,Dnmt3b is most highly expressed in long-term
HSCs relative to differentiated cells (Figure S1A available online).
To investigate the functional role of Dnmt3b, we generated
conditional KO mice by crossing Dnmt3bfl/fl and Dnmt3afl/fl
mice (Dodge et al., 2005) withMx1-cre mice in order to generate
inducible Dnmt3b-KO (3bKO) and Dnmt3a/Dnmt3b DKO mice.
We also compare data from these mice in some cases with
that from Dnmt3a-KO mice (3aKO; data generated here or from
Challen et al., 2012). The function of KO HSCs was examined
by competitive transplantation. Two-hundred-fifty HSCs (side
population+ c-Kit+ LinSca-1+) were transplanted into lethally
irradiated recipient mice along with 250 3 103 whole-bone-
marrow (WBM) cells from genetically distinguishable wild-type
(WT) mice (CD45 allelic differences; see the Experimental Proce-
dures). Floxedalleledeletionwas induced in donorHSCs4weeks
posttransplantation in order to avoid confounding effects of
Dnmt3 deletion in the niche or a requirement during homing.
Control mice throughout this study (unless otherwise specified)
consisted of Dnmt3bfl/fl, Dnmt3afl/flDnmt3bfl/fl (or similarly genet-
ically-matched) littermates that lacked Mx1-cre, which were
otherwise treated identically, including treatment with polyino-
sinic-polycytidylic acid (pIpC) in order to control for interferon-
mediated effects.
Analysis of peripheral blood chimerism in primary recipients
revealed no significant differences in mice transplanted with
3bKO or DKO HSCs in comparison to control HSCs (Figure 1A).
Given that 3aKO HSCs also did not exhibit a phenotype in
primary transplants (Challen et al., 2012), we performed serial
transplantation. HSCs were purified from primary recipients
18weeks posttransplant, and 250 HSCswere transferred to sec-
ondary recipients along with fresh WT competitor WBM cells.
Although 3bKO HSCs performed similarly to control HSCs,
blood production by DKO HSCs dropped precipitously
(Figure 1A), with a dearth of DKO-derived cells in all peripheral
blood lineages 16 weeks posttransplant (Figure S1B). In a third
round of transplantation, 3bKO HSCs continued to perform
similar to control HSCs but with a slight increase in B cell gener-
ation (Figure S1B). In contrast, DKOHSCs contributed to periph-
eral blood only transiently after the third round of transplantation
(Figure 1A). These phenotypes are markedly distinct from the
3aKO HSCs, which showed enhanced blood production relative
to control cells over four rounds of serial transplantation (Challen
et al., 2012).
Dnmt3b Enables Some HSC Differentiation in the
Absence of Dnmt3a
Self-renewal was evaluated by enumerating phenotypically
defined HSCs regenerated in the bone marrow 18 weeks after
each round of transplantation. In primary mice, the numbers of
HSCs generated from control and 3bKO was the same, but the
number of DKO HSCs was increased significantly (Figure 1B).
This behavior was exacerbated in subsequent rounds of
transplantation. In secondary recipients, input of 250 control
HSCs generated 6,692 ± 675 HSCs, whereas the same input
of DKO HSCs generated 305,472 ± 25,144 DKO HSCs. SimilarlyCell Sin tertiary transplants, 250 input control HSCs generated 3,061 ±
965 HSCs, whereas DKO HSCs produced 295,429 ± 37,813
HSCs (Figure S1C). The bone marrow of tertiary mice trans-
planted with DKO HSCs harbored nearly 50-fold more HSCs
than those from control or 3bKO transplanted recipients, with
nearly all of the HSCs derived from DKO cells (Figures 1C and
S1D) even though these animals were almost devoid of DKO-
derived peripheral blood cells (Figure 1A). DKO HSCs show
superior self-renewal in comparison to 3aKO with approximately
5-fold more HSCs generated in each round of transplant
(Figure 1B). However, unlike 3aKO HSCs, which retain some dif-
ferentiation capacity even after four rounds of transplantation
(Challen et al., 2012), the differentiation of DKO cells is deci-
mated after secondary transfer.
These data show that Dnmt3b plays a critical role in enabling
differentiation in the absence of Dnmt3a. Although loss of
Dnmt3a alone has a more dramatic effect than loss of Dnmt3b,
the effect of Dnmt3b is evidenced by the comparison between
3aKO and DKO. This concept is underscored when we
examine, on a per-HSC basis, the output of differentiation
(16-week white blood cell count per ul blood 3 the percentage
test-cell blood chimerism / number of donor-derived HSCs, the
‘‘differentiation quotient’’) versus self-renewal (the number of
donor-derived HSCs recovered at end of transplant per original
input HSC, the ‘‘self-renewal quotient’’) in each of the geno-
types (Figure 1D). The DKO HSCs resemble the 3aKO HSCs
in overall behavior, but the kinetics are distinct, with loss of
differentiation ability and increase in self-renewal apparent in
the first round of transplantation. Moreover, the self-renewal
capacity of the DKO HSCs is roughly 53 that of the 3aKO
HSCs on a per-cell basis.
This is consistent with the idea that the Dnmt3s serve as a crit-
ical regulators at the decision point between HSC differentiation
and self-renewal. Analysis of bone marrow progenitors in sec-
ondary transplants confirmed that the block in DKO differentia-
tion occurred predominantly at the level of the HSC (Figure S2)
with a dearth of all downstream progenitors (Figure 2A). More-
over, DKO HSCs were unable to differentiate well in vitro with
cytokine and stromal cell support. HSCs isolated at the end of
each round of serial transplantation and cultured in methylcellu-
lose with myeloid differentiation factors revealed a deficit in the
number of myeloid colonies produced from DKO HSCs in com-
parison to transplant-matched control HSCs (Figure 2B).
Although DKO HSCs could be serially replated (Figure S2D),
the colonies derived after the second plating were comprised
of an outgrowth of mast cells (Gr-1Mac-1c-Kit+FcεR1+) and
not the normal distribution of myeloid colonies (data not shown).
No difference was noted between control and 3bKO HSCs in the
same assay (Figures 2B and S2D). Genotyping of single-HSC-
derived colonies showed efficient excision of floxed alleles (Fig-
ures S2E–2G). Coculture of HSCs purified after secondary
transplant with OP9 stromal cells revealed a severe block in B
cell differentiation of DKO HSCs (Figure 2C) regardless of the
concentrations of lymphoid cytokines (IL-7 and Flt3L) or the
number of HSCs seeded per well (Figure 2D). These results
contrast with 3aKOHSCs, which were capable of robust myeloid
and lymphoid differentiation in vitro (Challen et al., 2012) and
reinforce the notion that Dnmt3b plays a critical role in enabling
HSC differentiation, particularly in the absence of Dnmt3a.tem Cell 15, 350–364, September 4, 2014 ª2014 Elsevier Inc. 351
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Figure 1. De Novo DNA Methylation Is Required for Long-Term HSC Differentiation In Vivo
(A) Donor-cell-derived peripheral blood chimerism in mice transplanted with control, Dnmt3b-KO (3bKO), or Dnmt3ab-dKO (DKO) HSCs. The previously
determined values for Dnmt3a-KO (3aKO) HSCs (Challen et al., 2012) are included for reference in the following panels.
(B) Enumeration of donor-derived HSCs per mouse 18 weeks posttransplant over serial transplantation.
(C) Bone marrow fluorescence-activated cell sorting analysis of tertiary transplanted mice showing accumulation of DKO HSCs.
(E) Differentiation and self-renewal quotients of HSC genotypes over serial transplant. Mean ± SEM values are shown (n = 16–35 recipient mice per genotype).
*p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S1.
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Figure 2. Dnmt3b Confers Some Differentiation Capacity in HSCs
(A) Frequencies of different cell compartments in the bone marrow of secondary recipient mice. White areas indicate the proportion of CD45.1+ (competitor-
derived) cells (n = 9–16). Statistical significance refers to comparisons of CD45.2+ (donor-derived) populations.
(legend continued on next page)
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Proliferation or Apoptosis
To further investigate the mechanisms of DKO HSC accumula-
tion in the bone marrow of transplant recipients, we performed
a kinetic analysis of HSC proliferation and apoptosis at monthly
intervals during secondary hematopoietic repopulation. At no
time point did DKO HSCs exhibit greater proliferation (measured
by Ki67 positivity) than control HSCs (Figure 2E), and both
populations increasingly entered quiescence over time. DKO
and control HSCs exhibited similar levels of AnnexinV staining,
indicating that the accumulation of DKO HSCs cannot be attrib-
uted to apoptosis resistance (Figure 2F). Altogether, these data
suggest that the accumulation of DKO HSCs is most likely a
result of cell divisions that almost exclusively result in symmetric
self-renewal rather than differentiation.
Ablation ofDnmt3a andDnmt3b in HSCsDrive Localized
DNA Methylation Loss
To address the epigenetic differences between Dnmt3 mutant
HSCs, we performed whole-genome bisulfite sequencing
(WGBS) of age-matched control versus tertiary-transplanted
3aKO and DKO HSCs. It was not possible to obtain sufficient
3bKO HSCs at the equivalent stage because of their limited
expansion. These studies differed from our previous compari-
sons of control and 3aKO HSCs (Challen et al., 2012) in (1)
comprehensive nature (WGBS instead of reduced representa-
tion bisulfite sequencing [RRBS]), (2) analysis at the tertiary
rather than secondary transplant stage, given that that is when
the DKO phenotype is most dramatic, and (3) control HSCs
used were from age-matched, untransplanted control mice
because of the limited number of posttransplant control HSCs
obtainable.
We generated between 1.1 and 1.2 billion raw reads for each
of three genotypes, covering nearly all 21 million CpGs in the
mouse genome (mm9) with an average depth of 403 to 473 (Ta-
ble S1). In comparison to control HSCs, 3aKO and DKO HSCs
showed a global decrease in DNA methylation (average CpG
methylation: 83.94% for control, 78.38% for 3aKO, and
78.01% for DKO; Figure 3A). Methylation was reduced across
all genomic features (Table S1) and genic elements (Figure 3B).
This contrast with our previous RRBS analysis, which indicated
no significant difference between control and 3aKO HSCs
(Challen et al., 2012), can be attributed to the bias of RRBS to-
ward CpG-dense genomic regions. To control for possible trans-
plantation effects on methylation (potentially masked by our use
of untransplanted control HSCs), we examined the impact of
transplantation as revealed by an independent study of aging
HSCs (Beerman et al., 2013). Comparison of CpGs covered by
both methods showed an average loss of DNA methylation of
11.8% in Dnmt3 mutant HSCs versus 6.9% because of trans-
plantation as identified by Beerman et al. (2013). Thus, we(B) Number of colonies generated per plate from HSCs at the end of each round o
96-well plates in Methocult media containing stem cell factor, IL-3, IL-6, and ery
(C) Flow cytometric analysis of B cell differentiation from control and DKO HSCs
(D) Numbers of B cells generated from control and DKO HSCs after 14-day cultu
(F) Dynamic analysis of HSC proliferation during secondary hematopoietic recon
(G) Dynamic analysis of HSC apoptosis during secondary hematopoietic reconsti
**p < 0.01, ***p < 0.001.
See also Figure S2.
354 Cell Stem Cell 15, 350–364, September 4, 2014 ª2014 Elsevier Icannot exclude some impact of transplantation itself, but the
loss of Dnmt3a/b has a much greater impact.
This high-sequencing coverage allowed quantification of dif-
ferential DNA methylation throughout specific genomic features,
for which we defined a change of ±33% of DNA methylation
(false discovery rate [FDR] < 0.05) as a differentially methylated
CpG (DMC) (Gu et al., 2010). One of the genomic loci that
showed the most dramatic DNA methylation changes was
repetitive elements (Table S2), with 66% and 61% of DMCs
within repeats in 3aKO and DKO HSCs, respectively, becoming
hypomethylated (Figure S3A). This included repetitive elements
targeted by the de novo DNA methyltransferases in ESCs
(Figure S3B). This hypomethylation was often associated with
increases in repeat expression (Figure S3C), reinforcing the
notion that one role of the Dnmt3s is to silence these repetitive
elements to safeguard the genome.
To examine whether ablation of the Dnmt3s affected DNA
methylation in specific gene sets, DMCs were grouped into
differentially methylated regions (DMRs), defined as at least
three neighboring DMCs of the same class (see the Experimental
Procedures). Because comparison of control versus mutant
methylomes identified over 70,000 DMRs across the genome
(Table S3), we initially focused on gene-associated DMRs
(defined as being within a gene or 3 kb upstream of transcription
start site or 3 kb downstream of transcription termination site).
Respectively, 92.5% (9,353/10,110) and 95.6% (8,765/9,171)
of DMRs in 3aKO andDKOHSCs became hypomethylated in co-
maprison to control HSCs (Table S3). Comparison of the DKO
with the 3aKO revealed fewer DMRs (3,495), of which the major-
ity showed a further loss of DNAmethylation after additional loss
of Dnmt3b. Most of the strongly hypomethylated DMRs were
conserved between the two mutant HSC genotypes (Figure 3C).
The most striking difference between 3aKO and DKO HSCs
was within CpG islands (CGIs). In comparison to control HSCs,
3aKO HSCs show a net gain of DNA methylation in CGIs,
whereas DKO HSCs experience a net loss of DNA methylation
like in other genomic features (Figure 3D). CGIs are the only
definable class of elements in the genome that exhibit this di-
chotomy (Figure 3D). Although CpGs within loci groups such
as ‘‘all’’ and ‘‘gene’’ contain similar proportions of hypomethy-
lated DMCs in 3aKO and DKO HSCs, there is a strikingly less
hypomethylation within CGIs from 3aKO HSC regardless of the
genomic context of where the CGI is located (Figure 3E). Of
the DMCs that were hypomethylated in both 3aKO and DKO
HSCs, there was enrichment for the distribution of these CpGs
within binding sites for transcription factors (TFs) important for
HSC regulation (Wilson et al., 2010) (Figure 3F). This may provide
an indirect mechanism for transcriptional changes in Dnmt3
mutant HSCs, as lower DNA methylation may influencing TF
binding, although how these DNA methylation changes alter
physical association of these sites with TFs remains to bef serial transplantation (n = 4). Single HSCs were sorted into individual wells of
thropoietin.
in vitro.
re (n = 5).
stitution with Ki67 staining (n = 4).
tution with AnnexinV staining (n = 3). Mean ± SEM values are shown. *p < 0.05,
nc.
Figure 3. Global DNA Methylation Defects
in Dnmt3 Mutant HSCs
(A) Distribution of all DMCs in the genome of
Dnmt3 mutant HSCs relative to control from
WGBS data.
(B) Average DNA methylation profile of CpGs
across genic elements in control, 3aKO, and DKO
HSCs.
(C) Distribution of DMCs within CGIs of Dnmt3
mutant HSCs compared to control.
(D) Average DNA methylation changes across
genomic elements in Dnmt3 mutant HSCs relative
to control.
(E) Percentages of hypomethylated DMCs within
genomic elements in Dnmt3 mutant HSCs in
comparison to control.
(F) Hypomethylated DMCs are enriched in tran-
scription factor binding sites. Hypermethylated
DMCs in 3aKO HSCs are enriched in CGIs.
See also Figure S3 and Tables S1, S2, and S3.
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in comparison to both control and DKO HSCs were specifically
enriched within CGIs (Figure 3F). These WGBS data suggest
that, although the additional loss ofDnmt3b augments the global
net loss of DNA methylation resulting from inactivation of
Dnmt3a, Dnmt3b contributes to inappropriate hypermethylation
of CGIs in in the absence of Dnmt3a.
We have recently shown that Dnmt3a maintains distinct sub-
sets of large DNA methylation lacunae that we termed ‘‘can-
yons’’ (Jeong et al., 2014). To examine the impact of additional
loss of Dnmt3b on canyons, we compared the sizes of the
3aKO canyons with DKO canyons. Of the canyons that previ-
ously contracted (largely harboring unexpressed genes), 78%
now expand in DKO HSCs (Figure S3D). Similarly, 27% of the
canyons that expanded in absence of Dnmt3a (harboring highly
expressed genes) are further enlarged in the DKO (Figure S3D).
These data demonstrate that like Dnmt3a, Dnmt3b is involved
in canyon size maintenance. Canyon views also demonstrate
the remarkable specificity of Dnmt3a and Dnmt3b action, exem-
plified by a distant perspective of the Meis1 and HoxA loci, in
which the associated canyon regions are eroded in 3aKO andCell Stem Cell 15, 350–364, SDKO HSCs, but methylation loss outside
these regions is minimal (Figures S3E
and S3F).
Dnmt3a and Dnmt3b Combine to
Epigenetically Repress the Stem
Cell Gene Network during HSC
Differentiation
To examine the effects of DNA methyl-
ation changes in 3aKO and DKO HSCs
on gene expression, we performed RNA
sequencing (RNA-seq) on the same cell
populations used for WGBS. With a
cutoff of FDR < 5%, there are 546 and
633 genes significantly upregulated and
downregulated, respectively, in 3aKO
HSCs in comparison to control HSCs(Table S4). Similarly, 549 and 514 genes were upregulated and
downregulated, respectively, in DKO HSCs in comparison to
control HSCs (Table S4). The majority of upregulated genes in
3aKO HSCs are also upregulated in DKO HSCs and vice versa
(Figure 4A). Furthermore, KEGG pathway analysis showed
many of the same functional categories enriched in both mutant
genotypes, such as upregulation of TGFb signaling. One diver-
gence was that MAPK signaling was enriched in 3aKO HSCs,
whereas Hedgehog signaling was enriched in DKO HSCs (Fig-
ure S4A). The genes downregulated in both mutant genotypes
involved cell cycle, niche interactions, and hematopoietic line-
age-specification programs (Figure S4B). Gene set enrichment
analysis on the genes significantly differentially expressed in
mutant HSCs correlated the genes upregulated in mutant
HSCs with genes increased in cells after exposure to the deme-
thylating agent 5-azacytidine (Figure S4C). There was no overlap
between the genes upregulated in 3aKO HSCs and downregu-
lated in DKO HSCs, and only four genes (Atp7b, Krt8, Clec11a,
andMxra8) that were downregulated in 3aKO HSCs but upregu-
lated in DKO HSCs (Figure 4B). Some differences in the outlier




Figure 4. The Dnmt3s Repress HSC-Specific Genes and Gene Expression Changes Are Explained by Epigenetic Dynamics
(A) Overlap of differentially expressed genes between Dnmt3 mutant HSCs and control HSCs.
(B) Plotting fold change in transcript expression of genes differentially expressed between 3aKO and control HSCs as the baseline. Overlay of fold change in DKO
HSCs relative to controls show a highly similar pattern.
(C) Identification of stem cell genes repressed by Dnmt3s during HSC differentiation. The baseline is RNA-seq expression of genes in control HSCs. Plot shows
increased expression in DKO HSCs, repression in control B cells, and intermediate expression (incomplete repression) in DKO B cells.
(D) The ratio of hypomethylated DMRs to hypermethylated DMRs shows enrichment for hypomethylation of Dnmt3-regulated genes relative to the rest of the
genome.
(legend continued on next page)
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exon 1 that is not present in control or DKO HSCs (Figure S4D).
We have previously shown that a major function of Dnmt3a in
HSCswas to epigenetically repress the stemcell genetic network
todownregulateHSCself-renewal genesandallowdifferentiation
(Challenet al., 2012). To examine thismodel in anunbiasedway in
the DKO situation, we performed RNA-seq on control and DKO-
derivedB cells after secondary transplantationwhen somediffer-
entiation capacity remained. To identify epigenetically regulated
genes, we selected genes that were upregulated >1.50-fold in
DKO HSCs in comparison to control HSCs, in control HSCs in
comparison to control B cells, and in DKO B cells in comparison
to control B cells; this defined a cohort of 254 genes (Table S4).
Setting the expression level of each gene in control HSCs as a
baseline, all genes have increased expression in DKO HSCs
and dramatically decreased expression in control B cells (Fig-
ure 4C). The role of the Dnmt3s in epigenetic repression of these
stem-cell-specific genes is clear because the expression pat-
terns for DKO B cells fall in between control HSCs and control B
cells. Independent analysis of DNA methylation patterns of this
cohort of 254 genes in DKOHSCs revealed that the ratio of hypo-
methylated to hypermethylated DMRs (compared to control
HSCs) was 50-fold (Figure 4D), significantly greater than the
average ratio throughout the genome or the average of all genes.
Thus, in normal hematopoiesis, these genes are predominantly
expressed in HSCs and are silenced by Dnmt3s during differenti-
ation. In the absence of the Dnmt3s this process is inefficient,
leading to enforced HSC self-renewal and incomplete repression
of stem-cell-specific genes in differentiated progeny.
Differential Gene Expression Can Largely Be Explained
by Epigenetic Dynamics
To gain insight into the influence of altered DNA methylation
on other epigenetic marks, we performed chromatin immuno-
precipitation (ChIP) sequencing (ChIP-seq) for the activating his-
tone mark H3K4me3 and the repressive mark H3K27me3. We
identified 14,494, 13,898, and 13,807 H3K4me3 peaks for con-
trol, 3aKO, and DKO HSCs, respectively, and 5,606, 4,358,
and 6,531 H3K27me3 peaks for control, 3aKO, and DKO
HSCs, respectively (Table S5) that were associated with gene
promoters (±3 kb of transcription start site). By overlaying
WGBS and ChIP-seq data, the majority of gene expression
changes in mutant HSCs can be explained by epigenetic
dynamics. Eighty four percent and 81% of the genes with signif-
icantly increased expression in 3aKO and DKO HSCs, respec-
tively, contained a hypomethylated DMR, increased H3K4me3,
decreased H3K27me3 (all epigenetic marks associated with
increased gene expression), or some combination of the three
epigenetic marks (Figures 4E and S4E). Conversely, 62% of
the genes significantly downregulated in 3aKO HSCs were
associated with an epigenetic mark more indicative of transcrip-
tional repression—either a hypermethylated DMR, decreased
H3K4me3, increased H3K27me3, or some combination (Figures(E and F) Categorical breakdown of genes differentially expressed in 3aKO and
Increased gene expression in 3aKO and DKO HSCs is dominated by hypomethy
activating chromatin (F). Activating histone, increased H3K4me3 and/or reduc
H3K27me3.
See also Figure S4 and Tables S4 and S5.
Cell S4F and S4E). However, only 47% of the downregulated genes
could be explained by the same phenomena in DKO HSCs (Fig-
ure 4F). Although DNA hypomethylation was the major driver of
increased gene expression in Dnmt3 mutant HSCs, loss of the
H3K4me3 histonemodification wasmore predictive of transcrip-
tional repression than changes in DNA methylation. These
altered epigenetic patterns had consequences for alternative
promoter utilization, an example being Tmcc3, for which the
longer isoform was exclusively observed in the mutant HSCs
(Figure S4F). This suggests that the Dnmt3s and DNA methyl-
ation influences chromatin patterns to cooperatively control
HSC self-renewal and differentiation cell fate decisions.
b-Catenin Signaling Contributes to the Block in DKO
HSC Differentiation
Ingenuity pathway analysis (IPA) was used to highlight potential
gene regulatory differences between 3aKO and DKO HSCs. IPA
discriminated the b-catenin (Ctnnb1) pathway to be dramatically
activated in DKO HSCs (the same pathway was slightly below
the IPA threshold for being considered activated in 3aKO
HSCs). Ctnnb1 transcript expression was significantly increased
in DKO HSCs (Figure 5A), and RNA-seq expression of validated
b-catenin target genes such as Ccnd1, Ppard, Vegfa, and Jag1
was also significantly increased (Figure 5B). Mouse models in
which HSCs constitutively express activated b-catenin show
similar phenotypes to DKO HSCs, such as an 8- to 15-fold in-
crease in the HSC pool and impaired differentiation in reconstitu-
tion assays (Scheller et al., 2006). We postulated that enhanced
activity of this pathwaymay be responsible for some of the differ-
entiation arrest of DKO HSCs.
DNAmethylation analysis of theCtnnb1 locus identified a DKO
hypomethylated region in the shore of the promoter CGI (Fig-
ure 5C). This created a new DNA methylation canyon (Figures
5D and S5A). Immunofluorescent staining of postsecondary
transplant HSCs (Figure 5E) showed an increase in nuclear
b-catenin in DKO HSCs (Figure S5B) as well as more total b-cat-
enin protein (Figure S5C). On the basis of an arbitrary cutoff of 0.2
mean fluorescence units, 81% of DKO HSCs showed nuclear
b-catenin in comparison to only 48%of control HSCs. To explore
whether this contributed to the differentiation deficit of DKO
HSCs, we ectopically expressed Axin in posttransplant HSCs.
Expression of the Wnt pathway inhibitor Axin in HSCs reduces
function by degrading b-catenin (Reya et al., 2003). Control
andDKObonemarrowprogenitors were transducedwith control
empty vector (MIG) or Axin-expressing (MIG-Axin) retrovirus and
cultured for 2 days. Then, viable GFP+ HSCs were purified
(LinSca-1+c-Kit+CD150+) and cocultured on OP9 stromal cells
in lymphoid cytokines. Enumeration of B220+CD19+ cells after
14 days of coculture showed that ectopic Axin expression was
able to partially rescue the in vitro B cell differentiation defect
of DKO HSCs but did not affect the number of B cells generated
from control HSCs (Figure 5F). We were able to elicit a similar
response through knockdown of Ctnnb1 transcript levelsDKO HSCs in comparison to controls according to their epigenetic status.
lation (E), whereas decreased gene expression is underpinned more by loss of
ed H3K27me3. Repressive histones, decreased H3K4me3 and/or increased






Figure 5. Increased b-Catenin Signaling Contributes to the Differentiation Block of DKO HSCs
(A) Real-time PCR analysis of Ctnnb1 transcript expression in HSCs (n = 3).
(B) RNA-seq expression of Ctnnb1 target genes in control (Ctl) and DKO HSCs.
(legend continued on next page)
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3aKO HSCs (Figure 5G). Given that overexpression of Axin pro-
duced a similar response to Ctnnb1 knockdown in terms of
b-catenin target gene response (Figure S5E), we tested whether
this strategy could also restore DKO HSC differentiation poten-
tial in vivo. Posttransplant HSCs were transduced with MIG
and MIG-Axin and transplanted into lethally irradiated mice.
Ectopic expression of Axin significantly enhanced peripheral
blood differentiation of DKO HSCs 8 weeks posttransplant (Fig-
ure 5H). Altogether, these data strongly support the notion that
the diminished differentiation activity of the DKO HSCs is due
at least in part to persistent b-catenin activation.
Abnormal Dnmt3b Activity in the Absence of Dnmt3a
Results in Aberrant CGI Hypermethylation
One puzzling observation was the finding that a specific subset
of CGIs in HSCs actually showed increased DNA methylation
levels after the ablation of Dnmt3a. Promoter CGI hypermethyla-
tion is a well-established cancer methylome phenotype (Fig-
ueroa et al., 2009; Shen et al., 2010, 2007), so this may be an
important mechanism in the early stages of HSC transformation.
In comparison to the control HSC methylome, 132 CGIs were
significantly hypermethylated in 3aKO HSCs (Figure 6A and Ta-
ble S6). The additional deletion of Dnmt3b abridged this effect,
resulting in only 60 hypermethylated CGIs (Figure 6A). Sixty three
CGIs were significantly hypermethylated in 3aKO HSCs in com-
parison to both control and DKO HSCs (Figure 6B). For genes
with hypermethylated CGIs in the promoter region such as
Fam32a,Mpi, and Praf2, this DNA hypermethylation was associ-
ated with gene repression (Figure 6C). One possibility was that
this CGI hypermethylation was actually increased 5-hydroxyme-
thylcytosine (5-hmC), and not 5-methylcytosine (5-mC) as bisul-
fite sequencing cannot discriminate between these epigenetic
marks. We examined the 5-hmC pattern of the 63 hypermethy-
lated CGIs with the use of 5-hmC profiles of control and 3aKO
HSCs (Jeong et al., 2014). Only two of the 63 hypermethylated
CGIs contained 5-hmC peaks in 3aKO HSCs (Figure S6A), sug-
gesting that the majority of this hypermethylation was due to
increased 5-mC. A recent epigenetic survey of ESCs deduced
that CpG-dense promoters (such as those containing CGIs)
are more likely to be repressed by the chromatin mark
H3K27me3, whereas CpG-poor promoters are more likely to
be epigenetically-regulated by DNA methylation (Xie et al.,
2013). For the 63 CGIs that gain DNA methylation in 3aKO
HSCs, 34 are marked by H3K27me3 in control HSCs, but only
nine are marked in 3aKO HSCs (Figure S6B), suggesting that
either of the two repressive marks was sufficient for silencing
of the locus.(C) DNA methylation profile of Ctnnb1 locus determined by WGBS. The green bo
(D) Bisulfite sequencing of hypomethylated Ctnnb1 region in HSC genotypes (op
(E) Immunofluorescent staining for Ctnnb1 (green) in control and DKO HSCs with
(F) Ectopic expression of Axin in DKO HSCs was able to partially rescue the B c
retrovirus (MIG). Ectopic expression of Axin in Ctl HSCs did not affect B cell diffe
(G) miRNA-mediated knockdown ofCtnnb1was also able to restore B cell in DKO
nonsilencing control miRNA; Ctnnb1, Ctnnb1 miRNA#1; n = 2).
(H) Peripheral blood chimerism following transduction and bone marrow transplan
to significantly increase peripheral blood differentiation in comparison to the co
*p < 0.05, **p < 0.01.
See also Figure S5.
Cell SAn alternative explanation suggested by these data is that in
the absence of Dnmt3a, abnormal function of Dnmt3b, may
lead to aberrant CGI hypermethylation as the hypermethylation
was lost when both enzymes were inactivated. To explore
this in HSCs, we analyzed DNA methylation patterns of tertiary
transplant control, 3aKO, and 3bKO HSCs by RRBS (Table
S6), which enriches for CGI-containing loci (Meissner et al.,
2008). RRBS and WGBS showed strong concordance, and all
63 CGIs in 3aKO HSCs exhibit hypermethylation with both
methods (Figure S6C). All of these CGIs were unmethylated in
the control, 3bKO and DKO HSCs (Figure S6D), strongly sug-
gesting that absence of Dnmt3a permits inappropriate Dnmt3b
action.
To confirm this mechanism, posttransplant control and DKO
bone marrow progenitors were transduced with a retroviral
vector encoding full-length Dnmt3b (MIG-Dnmt3b1) or control
(MIG). After 2 days, HSCs (GFP+ LinSca-1+c-Kit+CD150+
CD45.2+) were purified and assessed for DNA methylation by
bisulfite sequencing. Using the promoter CGI of Praf2 as an
example, hypermethylation is restricted to the 3aKO HSCs in
comparison to control, 3bKO, and DKO genotypes (Figure 6D).
Enforced expression of Dnmt3b1 in DKO HSCs resulted in
increased DNA methylation at this locus in comparison to DKO
HSCs transduced with MIG control, control HSCs transduced
with either MIG or MIG-Dnmt3b1, and untransduced HSCs (Fig-
ure 6E). This indicates that, at least for some loci, in the absence
of Dnmt3a, Dnmt3b functions abnormally in HSCs leading to
aberrant CGI hypermethylation and anomalous gene silencing.
Dnmt3b Isoforms in HSC Function and Cancer
DNMT3A mutations are prevalent in a range of hematopoietic
malignancies (Grossmann et al., 2013; Ley et al., 2010; Walter
et al., 2011; Yan et al., 2011), a finding congruent with the differ-
entiation arrest of mouse 3aKO HSCs. As we show Dnmt3b also
plays a role in enabling differentiation, it is surprising only two
DNMT3B point mutations have been reported in hematologic
cancers to date (Cancer Genome Atlas Research Network,
2013). Over 30 different Dnmt3b isoforms resulting from alterna-
tive promoter usage or alternative splicing have been reported
(Gopalakrishnan et al., 2009; Ostler et al., 2007; Xie et al.,
1999). Spatiotemporal patterns of isoform expression are largely
conserved between humans and mice (Okano et al., 1998), sug-
gesting that these isoforms carry biological significance, even
where splicing produces catalytically inactive proteins, such as
mouse Dnmt3b3, which lacks the catalytic motifs encoded by
exons 21 and 22. Moreover, transformation is known to change
the complement of DNMT3B isoforms, with aberrant forms
dominating in a number of malignancies (Ostler et al., 2007).x indicates hypomethylated region in DKO HSCs.
en circle, unmethylated CpG; closed circle, methylated CpG).
DAPI staining (blue) defining the nucleus.
ell differentiation defect in comparison to DKO HSCs transduced with control
rentiation compared to MIG control cells (n = 4).
HSCs but had no effect on B cell differentiation of 3aKOHSCs (N/S, scrambled
t of control and DKO HSCs. Ectopic expression of Axin in DKO HSCs was able
ntrol MIG vector (n = 9–10 mice per group). Mean ± SEM values are shown.
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Figure 7. Dnmt3b Isoform Expression and Tumor Suppressor Role in HSCs
(A) RNA-seq expression ofDnmt3b isoforms in control (Ctl) and 3aKOHSCs. Exons 21 and 22 encoding themethyltransferase domain ofDnmt3b1 are reduced in
3aKO HSCs.
(B) Ratio of Dnmt3b isoform expression in Ctl and 3aKO HSCs.
(C) Frequencies of genetic mutations in DNMT3A and DNMT3B in a range of tumors extracted from the COSMIC database.
(D) Overlap of DNMT3 mutations in patients with endometrial and colon cancer in COSMIC database.
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Dnmt3a and 3b Enable HSC DifferentiationTo consider these possibilities here, we examined the
expression of Dnmt3b isoforms in RNA-seq data and found
that only two Dnmt3b isoforms are expressed in control and
3aKO HSCs—Dnmt3b1 and Dnmt3b3 (Figure 7A). The predom-
inant isoform was Dnmt3b3, which generates a catalytically
inactive protein. This expression pattern is very similar to acute
myeloid lymphoma patients harboring DNMT3A mutationsFigure 6. CGI Hypermethylation in Dnmt3a-KO HSCs Is Mediated by D
(A) Comparison of differentially methylated CGIs across genotypes. Green triang
CGIs with statistically significant differences in DNA methylation.
(B) Identification of CGIs that are hypermethylated in 3aKO HSCs relative to con
(C) Gene expression and DNA methylation profiles of genes with hypermethylated
WGBS DNA methylation profiles. The height of each bar represents the DNA me
(D) Promoter CGI DNA methylation profile of Praf2 across HSC genotypes. Open
CpGs.
(E) DNAmethylation analysis of Praf2 promoter by bisulfite PCR following transdu
retrovirus, compared to untransduced (untrans) HSCs. ***p < 0.001.
See also Figure S6 and Table S6.
Cell S(Cancer Genome Atlas Research Network, 2013). Although
expression of both isoforms was slightly decreased in 3aKO
HSCs in comparison to control (Figure 7B), there was a larger
proportional decrease in Dnmt3b1 levels in 3aKO HSCs. This
suggests that there may be relatively little catalytically active
Dnmt3b in normal HSCs, which is decreased even further after
loss of Dnmt3a function. This most likely explains why 3bKOnmt3b
les indicate the genotype with increased DNA methylation. Red dots indicate
trol (Ctl) and DKO HSCs. Red line is the average DNA methylation profile.
promoter CGIs in 3aKO HSCs. Top, RNA-seq gene expression data; bottom,
thylation level of an individual CpG.
circles represent unmethylated CpGs, and closed circles represent methylated
ction of Ctl or DKOHSCs with a control (MIG) or Dnmt3b-expressing (Dnmt3b1)
tem Cell 15, 350–364, September 4, 2014 ª2014 Elsevier Inc. 361
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the 3aKO and DKO HSCs are similar at both the phenotypic
and molecular levels. Although the importance of Dnmt3b in
HSCs is clear as even residual Dnmt3b1 activity is sufficient
to maintain some differentiation capacity in 3aKO HSCs,
similar to a recent study showing that in the absence of
Dnmt3a, Dnmt3b functions as a tumor suppressor in chronic
lymphocytic leukemia and T cell malignancies (Peters et al.,
2014).
Given that Dnmt3a and Dnmt3b are broadly expressed during
embryonic development (Okano et al., 1999), we considered the
possibility that DNMT3A and DNMT3B mutations may play
similar roles in other tissues. In the Catalogue of Somatic Muta-
tions in Cancer (COSMIC) database (Bamford et al., 2004),
DNMT3Bmutations are detected in a range of solid tumors (Fig-
ure 7C) and often overlap with mutations inDNMT3A (Figure 7D).
This suggests that in some tissues, compound inactivation of de
novo DNAmethylation facilitates transformation, possibly reflec-
tive of a different spectrum of DNMT3B isoforms expressed in
these tissues. Although it is not possible to determine at this level
of analysis whether DNMT3A and DNMT3B are drivers of these
malignancies, given the data we present here, additional investi-
gation is clearly warranted.
DISCUSSION
We have demonstrated here a specific role for Dnmt3b in
permitting differentiation of HSCs. Although ablation of Dnmt3b
alone in HSCs produces only a modest phenotype, the function
of Dnmt3b is highlighted when inactivated in combination with
Dnmt3a; the synergistic impact of the DKO would not be pre-
dicted from factorial enhancement of the individual KOs. A pre-
vious study reported de novo DNA methyltransferase activity
was essential for self-renewal, given that Dnmt3afl/flDnmt3bfl/fl
HSCs transduced with a Cre retrovirus could not sustain
peripheral blood generation after bone marrow transplant
(Tadokoro et al., 2007). We observe a similar effect of DKO on
differentiation but also report extensive HSC expansion (self-
renewal), which may have been missed previously because of
the different experimental models (retroviral Cre and no serial
transplantation).
When coupled with histone ChIP-seq analysis, a clear
pattern for epigenetic regulation of gene expression in
Dnmt3 mutant HSCs emerged. The genes upregulated in
Dnmt3 mutant HSCs were underpinned by some combination
of loss of DNA methylation (defined by the presence of a hy-
pomethylated DMR) with a chromatin state more permissive
for gene transcription (decreased H3K27me3 and/or increased
H3K4me3). The genes downregulated in Dnmt3 mutant HSCs
were not generally associated with changes in DNA methyl-
ation but rather dominated by changes in the histone code.
Exactly how the chromatin architecture is instructed by the
Dnmt3s remains to be determined. Possibilities include direct
regulation of the writers and erasers of these marks by the
Dnmt3s, recruitment of polycomb group proteins to epigenetic
hotspots by the Dnmt3s or changes in DNA methylation pat-
terns causing conformational changes to the chromatin that
permits or inhibits access to other epigenetic regulators or
transcription factors.362 Cell Stem Cell 15, 350–364, September 4, 2014 ª2014 Elsevier ITheWnt/b-catenin pathway drives phenotypic HSC expansion
by inducing proliferation while simultaneously inhibiting
apoptosis and blocking differentiation (Perry et al., 2011), and
sustained canonical Wnt signaling in HSCs through constitu-
tively activated b-catenin causes a multilineage differentiation
block (Kirstetter et al., 2006; Scheller et al., 2006) reminiscent
of the Dnmt3 mutant HSC phenotype. Overexpression of Axin
was able to partly restore the differentiation capacity of DKO
HSCs, suggesting this pathway is a mechanism of HSC fate de-
cisions that is under epigenetic control. However, in addition to
Ctnnb1, there are surely other causative targets that contribute
to the enhanced self-renewal and differentiation arrest of
Dnmt3 mutant HSCs. For example, nuclear factor kB signaling
regulates HSC self-renewal (Stein and Baldwin, 2013; Zhao
et al., 2012), and Nfkb2 is overexpressed 4-fold in Dnmt3
mutant HSCs. Furthermore, loss of DNA methylation in TF bind-
ing sites after ablation of the Dnmt3s in HSCs (Figure 3F) may
alter binding of master regulators such as Gata2, Runx1,
Lmo2, and Scl, presenting an indirect mechanism with substan-
tial downstream consequences.
With the mild in vivo phenotype of 3bKO HSCs, our data sug-
gest Dnmt3a can compensate almost completely for Dnmt3b
loss, but Dnmt3b is only partially able to reciprocate in the
reverse situation. It is possible that the target specificity of
the remaining catalytically functional Dnmt3b is distinct, lead-
ing to aberrant DNA methylation patterns such as CGI hyper-
methylation. On a gross level, the phenotypes of 3aKO and
DKO HSCs are broadly similar. We propose this is because
the predominant Dnmt3b isoform expressed in 3aKO HSCs is
the catalytically inactive Dnmt3b3, resulting in quite minimal
levels of de novo DNA methylation activity in 3aKO HSCs.
Perhaps this explains the paucity of DNMT3B mutations in he-
matopoietic cancers because the relatively low level of catalyt-
ically competent DNMT3Bmeans there is no selective pressure
to genetically inactivate this gene after mutation of DNMT3A,
with the DNMT3A mutant cancer cells functionally operating
as a DNMT3A/B compound null. However, although the po-
tency of Dnmt3b is less than Dnmt3a in HSCs, even residual
levels of catalytic Dnmt3b clearly enable significant HSC
differentiation, as even after three rounds of serial transplanta-
tion the self-renewal quotient of 3aKO HSCs is 5-fold less than
that of DKO HSCs. The findings here build on the growing
appreciation for epigenetic regulation in stem cell function.
We show Dnmt3b has subtle, yet significant, roles in adult
HSCs. Understanding the fundamental roles of Dnmt3s and
DNA methylation in normal hematopoiesis is essential for
deducing the impact of DNMT3 mutations and altered DNA
methylation patterns in cancer.EXPERIMENTAL PROCEDURES
Animals
All animal procedures were approved by the International Animal Care andUse
Committee and conducted in accordance the Baylor College of Medicine and
Washington University in St. Louis institutional guidelines. All mice were
C57Bl/6 background distinguished by CD45.1 or CD45.2 alleles. Dnmt3afl/fl
and Dnmt3bfl/fl mice were obtained from the Beaudet lab at Baylor College
of Medicine (with the consent of En Li) and crossed to Mx1-Cre mice. For
bone marrow transplantation, recipient C57Bl/6 CD45.1 mice were trans-
planted by retro-orbital injection after a split dose of 10.5 Gy of lethalnc.
Cell Stem Cell
Dnmt3a and 3b Enable HSC Differentiationirradiation. 250 donor HSCs (CD45.2) were competed against 2.53 105 WBM
cells with the opposite CD45 allele (matched to the recipient). In competitive
transplantation experiments, deletion of floxed alleles in donor HSCs was
mediated 5–6 weeks posttransplantation in primary recipients. Conditional
deletion was mediated by six intraperitoneal injections (300 mg per mouse)
of pIpC (Sigma-Aldrich) in PBS every other day. For serial HSC transplantation,
WBM from transplanted recipients was isolated 18 weeks posttransplant, and
donor HSCs were repurified with CD45.2+SPKLS gating. Of these repurified
donor HSCs, 250 were competed against 2.5 3 105 fresh CD45.1 WBM.
PCR screening of Dnmt3a and Dnmt3b floxed allele deletion was performed
as previously described (Tadokoro et al., 2007).
Hematopoietic Stem Cell Purification and Flow Cytometry
For transplantation, HSCs were purified from the bone marrow with side pop-
ulation plus KLS (c-kit+Lin–Sca1+) gating (see also the Supplemental Experi-
mental Procedures). Bone marrow cells were stained for 90 min with Hoechst,
magnetically enriched for c-Kit+ cells, stained with additional antibodies, and
then purified by flow cytometric cell sorting.
Whole-Genome Bisulfite Sequencing
Using a Covaris sonication system (Covaris S2), 300 ng genomic DNAwas iso-
lated and fragmented. Libraries were constructed with the Illumina TruSeq
DNA sample preparation kit. After ligation, libraries were bisulfite-treated
with the EpiTech Bisulfite Kit (QIAGEN). Ligation efficiency tested by PCR
with TruSeq primers and Pfu Turbo Cx Hotstart DNA polymerase (Stratagene).
After determining the optimized PCR cycle number for each samples, a large-
scale PCR reaction (100 ml) was performed as described previously (Gu et al.,
2011). PCR products were sequenced with Illumina HiSeq sequencing sys-
tems. WGBS data analyses were based on model-based analysis of bisulfite
sequencing.
RNA-Seq
RNA was isolated from 70,000 HSCs with the RNeasy Micro Kit (QIAGEN).
Paired-end libraries were generated with Illumina TruSeq RNA sample pre-
paration kit. Illumina HiSeq was used for sequencing with a paired-end
sequencing length of 100 bp. The alignment was performed by RNA-seq uni-
fied mapper (RUM), which first mapped reads to the genome and transcrip-
tome by Bowtie and then used blat to remap those initially unmapped reads
to the genome. The information from the two rounds of mappings wasmerged.
The multiply mapped reads were discarded. The gene annotations used for
transcriptome alignment include RefSeq, University of California, Santa Cruz
(UCSC) knownGene and ensemble gene models. The gene expression, frag-
ments per kilobase of exon per million fragments mapped value, was calcu-
lated by counting the reads matching the exons of each gene. Differential
expression was performed with edgeR.
ChIP-Seq
ChIP was performed with 50,000 HSCs. ChIPed DNA was purified with a
MinElute Purification Kit (QIAGEN) and prepared for library construction
using ThruPLEX-FD preparation kit without extra amplification (Rubicon).
Sequencing was performed on a HiSeq 2000 (Illumina). Sequenced reads
were mapped to the mm9 mouse genome and peaks were identified by
model-based analysis of ChIP-seq data.
Statistical and Bioinformatic Analysis
See the Supplemental Experimental Procedures. All the RNA-seq, DNA
methylation, and histone ChIP-seq data can be visualized on the UCSC




All data have been uploaded to the NCBI Gene Expression Omnibus under
accession number GSE50793.Cell SSUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures,
six figures, and six tables and can be found with this article online at http://
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